Calabresi et al. reported that acquired plasma lecithin cholesterol acyltransferase (LCAT) deficiency was a major cause of low plasma HDL levels in patients with CKD, making it an attractive therapeutic target to reverse dyslipidaemia and reduce potential cardiovascular events (27). Here, LCAT is linked to hyperinsulinemic hypoglycemia, familial, 4.